Dr Mehra on the Evolution of HPV-Related Head and Neck Cancer Management

“For non–HPV-related cancers, there’s been a lot of interest in EGFR-directed therapy, and in particular, there are several EGFR [inhibitor–based] combinations [and] bispecific antibodies, which are being tested currently in the recurrent or metastatic [setting].”

Ranee Mehra, MD, director of Head and Neck Medical Oncology and a professor of medicine at the Marlene and Stewart Greenebaum Comprehensive Cancer Center at the University of Maryland Medical System, discussed the evolving therapeutic paradigm for patients with head and neck cancer.

Mehra began by explaining that recently reported data have mirrored the clinical interest surrounding EGFR-directed therapies for the treatment of patients with non–human papillomavirus (HPV)–related head and neck cancers. Referencing several structured analyses, Mehra emphasized that many EGFR inhibitor–based combinations and bispecific antibodies are currently undergoing rigorous testing within the recurrent and metastatic head and neck cancer settings. She highlighted that the clinical activity observed with these novel agents in these patient populations has been encouraging, offering a promising outlook for the integration of these therapies into standard disease management strategies.

Furthermore, Mehra addressed the strategic opportunity to transition these targeted interventions into earlier lines of treatment, suggesting that they may eventually play a critical role even in the potentially curable, locally advanced setting. Although she noted that these developments are effective treatment options for patients with HPV-negative head and neck cancers, she underscored the ongoing need to develop additional agents to study in the HPV-positive patient population. Mehra noted that new therapeutic avenues are essential for patients with HPV-positive head and neck cancers who have progressed after receiving standard therapies, necessitating a continued focus on research and the development of emerging agents. Overall, Mehra underscored the necessity of navigating complex clinical scenarios to tailor interventions to the individual needs of patients with head and neck cancers.